medwireNews

People with rheumatoid arthritis who switch between different biologic or targeted synthetic DMARDs have a higher risk for venous thromboembolism than those who remain on the same treatment, researchers report.

Results from the ADAPTeR study suggest that giving nivolumab before and after cytoreductive nephrectomy or metastatic biopsy may be a feasible strategy for patients with treatment-naïve metastatic clear cell renal cell carcinoma.

Analysis of data from the PACIFIC trial shows that levels of key patient-reported outcomes such as cough, fatigue, and quality of life, do not differ significantly between patients with advanced non-small-cell lung cancer treated with durvalumab after chemoradiotherapy and those who received placebo.

People with type 1 diabetes using the Tandem Control-IQ hybrid closed-loop insulin delivery system spent significantly more time within their target blood glucose range than people using a sensor-augmented insulin pump during 6 months of use in the iDCL trial.

Three-quarters of people who undergo islet transplantation for type 1 diabetes have sustained graft survival with associated improvements in glucose control, insulin requirements, and hypoglycemia incidence 10 years later, research shows.

Combining enfortumab vedotin with pembrolizumab could be a promising option for the first-line treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer, indicates the EV-103 trial.